Organization
University of Cincinnati/University of Cincinnati Medical Center
1 abstract
Abstract
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.Org: University of Cincinnati Medical Center, Mid-Florida Hematology Oncology, University of Cincinnati/University of Cincinnati Medical Center, University of Cincinnati College of Medicine, University of Cincinnati Cancer Institute,